EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis

Clinical Respiratory Journal

Volumn 12, Issue 4, 2018, Pages 1526-1535

  Doubková, Martina ^a   Švancara, Jan ^b   Svoboda, Michal ^b   Šterclová, Martina ^c   Bartoš, Vladimír ^c   Plačková, Martina ^d   Lacina, Ladislav ^e   Žurková, Monika ^f   Binková, Ilona ^a   Bittenglová, Radka ^g   Lošťáková, Vladimíra ^f   Merta, Zdeněk ^a   Šišková, Lenka ^h   Tyl, Richard ⁱ   Lisá, Pavlína ^c   Šuldová, Hana ^j   Petřík, František ^c   Pšikalová, Jana ^k   Řihák, Vladimír ^h   Snížek, Tomáš ^l   Reiterer, Pavel ^m   Homolka, Jiří ^c   Musilová, Pavlína ^l   Lněnička, Jaroslav ^m   Palúch, Peter ^c   Hrdina, Roman ⁿ   Králová, Renata ^o   Hortvíková, Hana ^d   Strenková, Jana ^b   Vašáková, Martina ^c   more..

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^e UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

^f PALACKÝ UNIVERSITY   (Czech Republic)

^g CHARLES UNIVERSITY   (Czech Republic)

^h Krajska Nemocnice T Bati as   (Czech Republic)

ⁱ Hospital Nový Ji ín   (Czech Republic)

^j University Hospital   (Czech Republic)

^k Krome í Hospital   (Czech Republic)

^l Jihlava Hospital   (Czech Republic)

^m Masaryk Hospital   (Czech Republic)

ⁿ Znojmo Hospital   (Czech Republic)

^o Hospital   (Czech Republic)

more..

Author keywords

idiopathic pulmonary fibrosis; IPF registry; prognostic factors; pulmonary functions

Indexed keywords

ACUTE DISEASE; ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CZECH REPUBLIC; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE REGISTRY; FACTOR ANALYSIS; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTED TOMOGRAPHY; HIGH RISK PATIENT; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SURVIVAL TIME; DIAGNOSTIC IMAGING; INCIDENCE; LUNG; LUNG VOLUME; META ANALYSIS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; REGISTER; RETROSPECTIVE STUDY; SURVIVAL RATE; TRENDS; VERY ELDERLY; VITAL CAPACITY; X-RAY COMPUTED TOMOGRAPHY;

AGED; AGED, 80 AND OVER; CZECH REPUBLIC; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INCIDENCE; LUNG; LUNG VOLUME MEASUREMENTS; MALE; MIDDLE AGED; PROGNOSIS; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; VITAL CAPACITY;

EID: 85045122005     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/crj.12700     Document Type: Article

References (44)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
2. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277–304.
3. Fernández-Pérez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence and clinical course of idiopathic pulmonary fibrosis. Chest. 2010;137(1):129–137.
4. Kolek V. Epidemiology of cryptogenic fibrosing alveolitis in Moravia and Silesia. Acta Univ Palacki Olomouc Fac Med. 1994;1:49–50.
5. Levinský L, Houštěk J, Hloušková Z, et al. Prevalence idiopatické difúzní intersticiální plicní fibrózy v ČSSR. Studia Pneumol Phtiseol Cechoslov. 1975;35(7):441–448.
6. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338.
7. Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3):511–522.
8. Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26(4):720–735.
9. Ley B, Collard HR, Talmadge E, King E. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431–440.
10. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz M, Brown KK. Changes in clinical and physiological variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168(5):538–542.
11. Gay SE, Kazerooni EA, Toews GB, et al. Idiopathic pulmonary fibrosis predicting response to therapy and survival Am J Respir Crit Care Med. 1998;57(4 Pt 1):1063–1072.
12. Kocova E, Vanasek J, Koblizek V, et al. Scoring of the radiological picture of idiopathic interstitial pneumonia: a study to verify the reliability of the method. Acta Radiol Open. 2015;4(11):2058460115605865
13. Šterclová M, Vašáková M, Dutka J, Kalanin J. Extrinsic allergic alveolitis: comparative study of the bronchoalveolar lavage profiles and radiological presentation. Postgrad Med J. 2006;82(971):598–601.
14. Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med. 2006;147(7):803–809.
15. Hanson D, Winterbauer RH, Kirtland SH, Wu R. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest. 1995;108(2):305–310.
16. Jegal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171(6):639–644.
17. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35(2):830–836.
18. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810–816.
19. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997;115(1):242–248.
20. Kim DS, Dollare HR, King JRTE. Classification and natural history of idiopathic interstitial pneumonias. Proc Am Thorac Soc. 2006;3(4):285–292.
21. Alakhras M, Decker PA, Nadrous HF, Collazo-Clavell M, Ryu JH. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. Chest. 2007;131(5):1448–1453.
22. Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005;26(4):586–593.
23. Kurashima K, Takayanagi N, Tsuchiya N, et al. The effect of emphysema on lung function and survival in patients with idiopathic pulmonary fibrosis. Respirology. 2010;15(5):843–848.
24. Mejía M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest. 2009;136(1):10–15.
25. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129(3):746–752.
26. Schmidt SL, Nambiar AM, Tayob N, et al. Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J. 2011;38(1):176–183.
27. Sugino K, Ishida F, Kikuchi N, et al. Comparison of clinical characteristics and prognostic factors of combined pulmonary fibrosis and emphysema versus idiopathic pulmonary fibrosis alone. Respirology. 2014;19(2):239–245.
28. Mura M, Porretta MA, Bargagli E, et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J. 2012;40(1):101–109.
29. Selman M, Carrillo G, Estrada A, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behaviour and gene expression pattern. PLoS One. 2007;2(5):e482
30. Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med. 2013;1(4):309–317.
31. King TE, Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001;164(7):1171–1181.
32. Barlo NP, van Moorsel CH, van den Bosch JM, Grutters JC. Predicting prognosis in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung. 2010;27(2):85–95.
33. Carbone R, Balleari E, Grosso M, Montanaro F, Bottino G, Ghio R. Predictors of mortality of idiopathic pulmonary fibrosis. Eur Rev Med Pharmacol Sci. 2008;12(2):97–104.
34. Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005;172(4):488–493.
35. Sumikawa H, Johkoh T, Colby TV, et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med. 2008;177(4):433–439.
36. King TE, Jr, Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis. Relationship between histopathologic features and mortality. Am J Respir Crit Care Med. 2001;164(6):1025–1032.
37. Noble PW, Albera C, Bradford WZ, et al. CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–1769.
38. King TE, Jr., Bradford WZ, Catro-Bernardini S, et al. ASCEND Study Group. A phase 3 trials of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092.
39. Richeldi L, Du Bois RM, Raghu G, et al. INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082.
40. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684–691.
41. Du Bois RM, Weycker D, Albera C, et al. Ascertainment if individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(4):459–466.
42. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis. A composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167(7):962–969.
43. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005;142(12 Pt 1):963–967.
44. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636–643.